Skip to main content

RocketVax raises fresh capital

| News

RocketVax raises fresh capital

07.02.2023

The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further develop a second-generation vaccine to combat the SARS-CoV-2 virus.

RocketVax AG has successfully raised further capital after closing a financing round, which was led by the Foundation of Urs and Simone Wietlisbach. The foundation acquired a 9 percent stake in RocketVax as well. Urs Wietlisbach is the co-founder of the Partners Group, a Zug-based investment firm.

According to a press release, the additional funding will above all be put towards further developing a second-generation vaccine against the SARS-CoV-2 virus. “Despite the very difficult environment, we have managed to secure reputable investors who have invested significant amounts”, comments Dr. Vladimir Cmiljanovic, Vice President of RocketVax, before adding: “We still believe that the RocketVax vaccine is urgently needed”.

Partnership with Basel-based institutions

The Basel-based biotech startup was founded in 2020 as a subsidiary of the startup incubator and accelerator Swiss Rockets AG. The company operates on the basis of a collaboration between Swiss Rockets, Gigabases Switzerland AG, a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH), the University Hospital of Basel, ETH Zurich itself, the University of Zurich and the University of Basel, as well as the Swiss Tropical and Public Health Institute. It is working in parallel on the development of three live attenuated vaccines. Two of these COVID-19 serums are slow replicating SARS-CoV-2 viruses, while the third is based on a genetically engineered SARS-CoV-2 virus that cannot replicate.

The advantage of these is that they not only protect the immune system by producing spike antibodies, but also generate a wide range of other antibodies and T cells. According to RocketVax, this should provide longer-lasting protection against wild-type viruses and virus variations. In addition, the vaccine is said to be very stable at ambient temperatures, which should also allow it to be administered to people in warmer and poorer countries.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.